A time-resolved fluoroimmunoassay to assay the rabies virus glycoprotein: application for estimation of human rabies vaccine potency

Guanfeng Lin1, Shaolang Chen2, Hui Zhao3, Junyu Liang2, Qiaoting Deng2, Rongliang Liang2, Xinxin Guo2, Zhenhua Chen2, Baihong Chen1, Tiancai Liu2,4 & Yingsong Wu2,4

Replacement of the in vivo rabies vaccine potency test (NIH test) by in vitro methods had been discussed by several researcher including WHO expert working groups. In this paper, a time-resolved fluoroimmunoassay (TRFIA) for the assay of rabies virus glycoprotein in rabies vaccine was first established to estimate the rabies vaccine potency by using specific monoclonal antibody that only recognized the native, trimeric and immunogenic form of rabies virus glycoprotein. Potency of the rabies virus glycoprotein was assayed with satisfactory performance under optimal conditions, and the method demonstrated satisfactory results when applied in practical samples. The correlation coefficient of potency values obtained from the present TRFIA and ELISA was 0.912, and 0.903 for those from the present TRFIA and NIH test. These preliminary results confirmed that this TRFIA can replace ELISA with higher performance, and could be a promising replacement of the NIH test. Based upon these results, the present TRFIA seemed to be a convenient tool for evaluating rabies vaccine potency and its products at different stages accordingly.

Rabies is an endemic and fatal zoonotic disease, and causes 55,000 human rabies deaths in more than 150 countries and regions per year1. Although significant scientific has been made, rabies remains a serious zoonotic disease globally and continues to present challenges for public health safety. Fortunately, rabies is a preventable disease and vaccination is considered as the most viable and cost-effective method for prevention of it refs 2 and 3. Over 15 million people in the world are receiving multi-dose post-exposure prophylaxis to prevent rabies annually4. Safe and efficacious vaccines are needed in prevention and post-exposure therapy.

Vaccine potency testing is necessary to evaluate the immunogenicity of inactivated rabies virus vaccine preparations before application5. Currently, the National Institutes of Health (NIH) test is recommended by the WHO expert committee to evaluate potency of rabies virus vaccine. However, NIH test has numerous disadvantages such as poor precision, significant variability, inherent concerning cost, violation of animal welfare and biosafety requirements6,7. As a result, there is increased exposure in human beings to live and virulent rabies strains. The NIH test also requires a secure biosafety level 3 facility for housing and challenging the experimental animals. The replacement of the NIH test for rabies vaccine evaluation by in vitro methods had been discussed in several research and also by WHO expert working groups8. The viral genome of rabies virus produces five monocistronic mRNAs encoding the nucleoprotein, phosphoprotein, matrix protein, transmembrane glycoprotein and the viral RNA-dependent RNA polymerase9. The amount of

1Teaching and Scientific Research Center, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China. 2Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China. 3Department of Human Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China. 4Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University Guangzhou, Guangzhou, China. Guanfeng Lin, Shaolang Chen and Hui Zhao contributed equally to this work. Correspondence and requests for materials should be addressed to Y.W. (email: wg@smu.edu.cn)
immunogenic rabies virus glycoprotein decides the vaccine potency in the vaccine preparation\(^{19}\), and using specific glycoprotein monoclonal antibody (MAb) to evaluate the rabies vaccine potency has been recognized and applied. Several *in vitro* methods have been proposed for the evaluation of vaccines potency based on rabies virus glycoprotein quality and quantity, which is expected to correlate with vaccine potency\(^{25,8,10–17}\). However, the method in almost of the previous reports was enzyme-linked immunosorbent assay (ELISA) method or based on the extension of ELISA. Due to the characteristics of enzyme conjugates, limitations of ELISA such as low sensitivity, instability, imprecision, narrow detection range and more time consumption are obvious. Therefore rapid, precise and sensitive *in vitro* detection method is needed for the quality control of rabies vaccine. Using europium (Eu) chelates as the labels, Time-resolved fluoroimmunoassay (TRFIA) was considered as a successful non-isotopic detection method since it was first reported by Lovgren et al.\(^{18}\), and had been noticed as an excellent detection method and employed in sorts of biomedical sciences fields\(^{19–26}\). Time-resolved fluoroimmunoassay gets excellent precision, higher sensitivity and extremely wider detection range relative to traditional ELISA\(^{27}\). Application of TRFIA for detecting viral proteins antigen had been proven to be very applicable by us in the past research\(^{23,24}\). For acute infectious diseases such as hepatitis B, TRFIA with high sensitivity can assay low level of viral protein in the early stages for disease diagnosis. Although high sensitivity may be not very important for the detection of rabies virus protein, TRFIA with extremely wider detection range, excellent precision and simple operation can greatly save the operation time and workload with much precise and accurate determinations. Using specific MAb that only recognized the native, trimeric and immunogenic form of rabies virus glycoprotein prevented detection of non-immunogenic soluble glycoprotein in vaccines, we herein first designed a novel TRFIA which was designed to estimate the potency of human rabies vaccines by assaying glycoprotein in rabies vaccines, and may have utility in replacement of the NIH test. Thus, the aim of our study was to establish this novel TRFIA and validate its application. This study involved measurement of parameters, such as sensitivity, precision, recovery, linearity and feasibility.

**Materials and Methods**

**Virus, cell, animal and Samples.** The Challenge Virus Strain (CVS) rabies virus and aG strain rabies virus human vaccine were kindly provided by Guangzhou Promise Biologic Products (Guangzhou, China). Purified glycoprotein was prepared by Guangzhou Promise Biologic Products (Guangzhou, China), which was extracted from the rabies virus grown in Vero cell with mild non-ionic detergents and then purified by isoelectric focusing in a sucrose gradient. Sp2/0 cell was stored in Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University (Guangzhou, China). 6–8 weeks old female, BALB/c mice used in this study were procured from Experimental Animal Center, Southern Medical University (Guangzhou, China). Other samples were kindly provided by Guangzhou Promise Biologic Products (Guangzhou, China) and were stored at −80 °C. This study had been approved and registered by the laboratory animal welfare and ethics committee of Southern Medical University (Guangzhou, China). The care and use of the animals conform to the Institutional Animal Ethics Committee guidelines.

**Reagents and instrumentation.** Bovine serum albumin (BSA), Tween-20, triton X-100, β-naphthyltrifluoroacetate, tri-n-octylphosphine oxide and tris were procured from Sigma-Aldrich (St. Louis, MO, USA). Sephadex G-50 was purchased from Amersham Pharmacia Biotech (Piscataway, NJ, USA). The Rabies Virus Glycoprotein ELISA Kit (EIA-2489) was procured from DRG Instruments GmbH (Marburg, Germany). Pierce™ BCA Protein Assay Kit (23225) was procured from Thermo Fisher Scientific (Waltham, MA, USA). Eu\(^{151}\)-labeling kit, the Victor™ 1420 multilabel counter and 96-well plates were procured from PerkinElmer WALLAC (Turku, Finland). Ultra-pure water obtained using a Milli-Q water purification system (Millipore, MA, USA) was used throughout the experiments. Other chemicals and reagents used were of analytical grade and used without further purification.

**Preparation of monoclonal antibodies.** Monoclonal antibodies were prepared using standard protocols by immunizing 6–8 weeks old female BALB/c mice with rabies virus (aG strain)\(^{18}\). The spleen cells isolated from those BALB/c mice were fused with Sp2/0 cells to prepare the hybridoma. The hybridoma cells secreting monoclonal antibodies against glycoprotein of rabies proteins were screened by indirect immunofluorescent assay with purified glycoprotein, and the monoclonal hybrids were selected after two rounds of single cell cloning. Paired anti-glycoprotein MABs (S053 and S036) were selected for further study.

**Solutions.** Coating buffer was 50 mM Na\(_2\)CO\(_3\)-NaHCO\(_3\) buffer (pH 9.6). Blocking solution was 50 mM Na\(_2\)CO\(_3\)-NaHCO\(_3\) buffer (pH 9.6) containing 1% BSA. Labeling buffer was 50 mM Na\(_2\)CO\(_3\)-NaHCO\(_3\) (pH 8.5) with 155 mM NaCl. Elution buffer was 50 mM Tris-HCl (pH 7.4) with 0.2% BSA and 0.9% NaCl. Standard buffer was 50 mM Tris-HCl (pH 7.8) containing 0.1% Na\(_2\)CO\(_3\) and 0.2% BSA. Assay buffer was 50 mM Tris-HCl (pH 7.8) with 0.02% BSA, 0.05% Tween-20 and 0.05% Na\(_2\)CO\(_3\). Enhancement solution was 100 mM acetate-phthalate buffer (pH 3.2) containing 15 μM β-naphthyltrifluoroacetate, 50 μM tri-n-octylphosphine oxide and 0.1% triton X-100. Washing buffer was 25 mM Tris-HCl (pH 7.8) with 0.9% NaCl and 0.06% Tween-20.

**Immobilization of MAB.** Each well of the standard, bare 96-well plates was coated with 250 ng of anti-glycoprotein MAB (S036) diluted in 100μl coating buffer and incubated overnight at 4 °C. After three times washing, blocking solution (250μl) was added to the well for blocking the coated surface for 1 h at 37 °C. Finally, the 96-well plates were dried in a high vacuum, and then stored at −20 °C in a sealed plastic bag with desiccant.
Labeling of MAb. According to the protocol provided by the Eu³⁺-labeling kit, anti-glycoprotein MAb (S053) was labeled with Eu³⁺-chelates. Briefly, 400 μg of Eu³⁺-chelates was gently mixed with 2 mg MAB S053 in 200 μl labeling buffer and incubated with continuous gently shaking for 18 h at room temperature. Then the mixture was separated by a Sephadex G-50 column. Purified Eu³⁺-MAb conjugates were eluted with a descending elution buffer, and collected (1.0 ml per fraction). The protein concentration of Eu³⁺-MAb conjugates in collected fraction was measured by the Pierce™ BCA Protein Assay Kit. The fluorescence of Eu³⁺-MAb conjugates diluted with enhancement solution (1:100) was detected in microtitration wells (200 μl per well). Fractions from the first peak with the highest Eu³⁺ count were pooled and characterized. After dilution with elution buffer containing 0.2% BSA as a stabilizer, purified conjugate was rapidly lyophilized under high vacuum and stored at −20 °C.

Preparation of standards. After being extracted and purified as described above, potency value of purified glycoprotein was detected by the ELISA kit (EIA-2489) for preparing standards. Standards in the seven mixed standards were prepared by diluting purified rabies glycoprotein in standard buffer as 0, 31.25, 62.5, 125, 250 and 500 international units per milliliter (IU/ml).

Immunoassay design. As shown in Fig. 1, the assay was performed using the one-step procedure. Following the immobilization and antibody labeling protocols described above, 50 μl of standards or samples and 100 μl of assay buffer containing 400 ng of Eu³⁺-labeled MAb S053 were added into each well with immobilized MAb S036. After one-hour incubation with continuous slow shaking, immobilized MAb, samples or standards and the Eu³⁺-labeled MAb made up a sandwich-type format in wells. Then, the wells were washed for 6 times and filled with 100 μl of enhancement solution. The plates were shaken for 5 min at room temperature and then the fluorescence intensity was measured on the Victor™ 1420 Multilabel Counter equipped with filters for Eu³⁺ (excitation wavelength, 340 nm; emission wavelength, 613 nm; delay time, 0.40 ms; window time, 0.40 ms; cycling time, 1.0 ms).

NIH test. As per the guidelines of the Institutional Animal Care and Use Committee (IACUC), Southern Medical University, for prevention and control of rabies, the NIH test was carried out in BALB/c mice following standard procedures. Five-fold serial dilutions of the unknown vaccine and reference vaccine were prepared for immunizing 12–14 g mice by intraperitoneal injection with 0.5 ml dose. Mice were immunized again with the same procedure after one week. The fourteenth day after the first time immunization, intracerebral challenge with lethal dose of CVS strain was performed for the mice. The mice was observed and recorded daily for morbidity and mortality until the twenty-eighth day since the first time immunization. Potency value of the vaccine sample was calculated by using the Reed-Muench method. Thirty nine vaccine samples were tested using the present TRFIA method and the potency of each vaccine sample was re-evaluated using NIH test.

Statistical analyses. Analysis of data was performed using Statistical Product and Service Solutions (SPSS) software (version 20.0, SPSS Inc., Chicago, IL). Two-tailed test was applied for statistical analysis in all tests with alpha level set at α = 0.05. A P value of less than 0.05 (P < 0.05) was considered statistically significant. Because the fluorescence signal value is too large, a logarithmically transformed data was employed for curve fitting. Standard curves were obtained by plotting the logarithm of fluorescence intensity (Y) against the logarithm of the sample value (X) and fitted to a four-parameter logistic equation using Origin7.5 SR1 (Microcal, USA): LogY = A × LogX + B.

Results

Fitting standard curve for the relationship between concentration and fluorescence signal. Fluorescence signal was carried out following our immunoassay design with a series dilution of standards (0, 31.25, 62.5, 125, 250 and 500 IU/ml) obtained from 10 separate assays. As shown in Fig. 2, Coefficients of variation of each standard were less than 10% for fitting the standard curve. For the standard curve depicted in Fig. 2,
the best-fit calibration was determined to be described by the following equation: \( \log Y = 1.04 \times \log X + 2.66 \) \((r^2=0.998, P<0.0001)\). As fluorescence signal value of the unknown sample is collected by the instrument, the sample will be quantitative determination by using this equation. Signal saturation (hook effect) means falsely low values on an immunoassay when an overwhelming amount of antigen affects the binding capacity of the added antibody, especially when using the double antibody sandwich method. As shown in Fig. 3, signal saturation appeared when the dose exceeded 1 000 IU/ml for the present method. This means that when the dose exceeds 1000 IU/ml, the relationship between concentration and fluorescence signal no longer meet the linear relationship of the fitting equation.

The minimum detectable dose of the present method for assaying glycoprotein potency. The minimum detectable dose was determined by adding two standard deviations (SD) to the mean \((\text{mean} + 2 \times \text{SD})\) optical density value of twenty zero standard replicates and calculating the corresponding concentration. According to this calculation method, a value of 0.098 IU/ml was identified as the minimum detectable value of the present method for potency assay of glycoprotein (Table 1).

Repeatability and recovery test for the present method. The intra-assay and inter-assay precision were analyzed using three samples and the same batch of reagents on separate days as shown in Table 2. Total coefficient of variations of the present assay ranged from 2.9% to 4.9%. As expected, the repeatability of the present assay was remarkably low, neither of imprecision was significant (>10%). The general analytical recovery of the assay was in the range of 90–110%. Therefore the accuracy of the measurements will be guaranteed by the present method.
Dilution linearity test for the present method. For linearity testing, serial dilutions of the three glycoprotein samples (33.1, 90.1 and 214.2 IU/ml) were prepared and the potency of each dilution was determined by the present method. Table 3 showed the dilution linearity of this assay when we used samples serially diluted with assay buffer, expected values were derived from initial value of potency in the undiluted samples. Correlating the results obtained from assay with the expected values, we found that the expected values were identical with measured values. This result confirmed that the detection would not be affected if the sample was diluted with assay buffer.

Comparison of assay results and performance for the present TRFIA and ELISA. According to the published data in the protocol provided by the Rabies Virus Glycoprotein ELISA Kit (EIA-2489), comparison of assay performance for the present TRFIA and ELISA was shown in Table 4. Potency values of glycoprotein in 189 samples including rabies samples, semi-finished vaccine samples, unqualified and qualified vaccine samples were assayed by the present TRFIA and ELISA, respectively. As shown in Fig. 4. The correlation coefficient of potency values obtained from the present TRFIA method and ELISA method was excellent, with a regression equation: $Y = 1.00 \times X + 1.38 \quad (r^2 = 0.912, P < 0.0001)$.

Comparison of potency values obtained from the present TRFIA and NIH test. Thirty nine vaccine samples were tested by the present TRFIA method and the potency of each sample was re-evaluated using the NIH test. As shown in Fig. 5, the variation tendency of results obtained from TRFIA method and NIH test

| Number of replication | Mean | Standard deviation | Mean + 2*SD | Minimum detectable dose |
|-----------------------|------|--------------------|------------|-------------------------|
| 20                    | 575  | 23                 | 621        | 0.098 IU/ml             |

Table 1. Repeated measure of zero standard for assaying the minimum detectable dose.

| Samples | Nominal value (IU/ml) | Mean ± SD (IU/ml) | CV (%) | Recovery (%) |
|---------|-----------------------|-------------------|--------|--------------|
| Intra-assay (n=10) | | | | |
| A | 46.1 | 44.6 ± 1.83 | 4.1 | 96.7 |
| B | 70.1 | 68.9 ± 2.68 | 3.9 | 98.2 |
| C | 124.2 | 126.1 ± 3.65 | 2.9 | 101.5 |
| Inter-assay (n=12) | | | | |
| A | 46.1 | 45.8 ± 2.24 | 4.9 | 99.3 |
| B | 70.1 | 71.3 ± 2.64 | 3.7 | 101.7 |
| C | 124.2 | 128.4 ± 4.36 | 3.4 | 103.4 |

Table 2. Repeatability and recovery of the present TRFIA. CV: coefficient of variation. SD: standard deviation.

| Sample | Dilution | Value (IU/ml) | Expected | Observed (n=3) | Recovery |
|--------|----------|---------------|----------|---------------|----------|
| A      | NA       | 33.1          |          |               |          |
| 1:2    | 16.6     | 17.1          | 103.0%   |               |          |
| 1:4    | 8.3      | 8.1           | 97.6%    |               |          |
| 1:8    | 4.1      | 4.0           | 97.6%    |               |          |
| 1:16   | 2.1      | 2.2           | 104.8%   |               |          |
| B      | NA       | 90.1          |          |               |          |
| 1:2    | 45.1     | 46.5          | 103.1%   |               |          |
| 1:4    | 22.6     | 23.2          | 102.6%   |               |          |
| 1:8    | 11.3     | 10.9          | 96.5%    |               |          |
| 1:16   | 5.7      | 5.8           | 101.8%   |               |          |
| C      | NA       | 214.2         |          |               |          |
| 1:2    | 107.1    | 106.5         | 99.4%    |               |          |
| 1:4    | 53.6     | 54.9          | 102.4%   |               |          |
| 1:8    | 26.8     | 27.5          | 102.6%   |               |          |
| 1:16   | 13.4     | 12.8          | 95.5%    |               |          |

Table 3. Dilution Linearity test of the present TRFIA. NA, not applicable.
was basically the same for those thirty nine vaccine samples. The comparisons of potency values obtained from these two methods were shown in Fig. 6. The correlation coefficient of potency values obtained from the present TRFIA method and NIH test was excellent, with a regression equation:

\[ Y = 1.00 \times X + 1.38 \]

\[ R^2 = 0.912 \]

\[ P < 0.0001 \]

Table 4. Comparison of assay performance for the present TRFIA and ELISA.

| Method  | Recovery | Imprecision | Operating time | Maximum quantitative value |
|---------|----------|-------------|----------------|---------------------------|
| TRFIA   | 96.7–103.4% | 2.9–4.9% | 1.5 h | 1 000 IU/ml |
| ELISA   | 80–120% | <20% | 3 h | 25 IU/ml |

Figure 4. Graphical comparisons of the present TRFIA and ELISA results for assay of rabies virus glycoprotein.

Figure 5. Result of TRFIA and NIH method for thirty nine rabies vaccine samples.

Discussion

In spite of all drawbacks, the NIH test still represents the “gold standard” against which any alternative method is judged. However, NIH test’s own shortcomings determine that it is not suitable for large-scale use in the actual production process of rabies vaccine. In this case, vaccine manufacturers have to choose ELISA method for monitoring the quality control in each stage of vaccine production. As we know, ELISA cannot assay sample with very good performance and rapid detection. So the main aim of this work was to provide a more suitable in vitro method for the replacement of the in vivo potency test for rabies vaccine in the different stages of vaccine production process.

Fluorescence immunoassay, like other immunoassays involving non-isotopic labeling, has been well accepted as a stable, inexpensive, rapid, and sensitive method. However, conventional fluorescent labeling has a limited
success in assay of analyte because of its high background, short decay time and broad spectrum, which make it difficult to be a qualified labeling for excellent quantitative analytical technique. Up to now, fluorescent lanthanide is a favorable choice owing to its excellent Stokes shift. Its lifetime ranges 50–1000 μs (over four decades longer than the average background duration) depending on the temperature and the solvent presented. These features can be utilized for optimization of the measurement conditions to get the maximal sensitivity and to minimize the signal spillover. As the application of TRFIA for quantification of rabies virus nucleoprotein in rabies vaccines was first reported by our research team, TRFIA had been successfully introduced into the rabies vaccine field. As a successful replacement of ELISA, this nucleoprotein TRFIA was highly praised by the vaccine producers. Those preliminary research results had confirmed that TRFIA could be a reliable and interesting methodology in the field of rabies vaccine. Glycoprotein levels in a vaccine are often regarded as a surrogate for tests of vaccine potency. So we choose TRFIA method to be the suitable in vitro method for assaying rabies virus glycoprotein in rabies vaccine by using specific MAbs.

Monoclonal antibodies against this linear epitope of nucleoprotein have the potential to recognize native rabies virus nucleoprotein, and expression of the nucleoprotein gene of rabies virus can be used as immune antigen and diagnostic reagent. So the preparation of nucleoprotein MAb will be carried out very smoothly. But unlike nucleoprotein MAb, specific glycoprotein MAbs used in this TRFIA have to recognize glycoprotein molecules folded in the native form, and without detecting the glycoprotein monomeric forms (such as soluble glycoprotein) which are poor immunogens. Our research team spent a lot of work on the preparation of those specific glycoprotein MAbs in our laboratory. Fortunately, paired anti-glycoprotein MAbs (S053 and S036) were successfully screened out. Correlation coefficient (r² = 0.912) for TRFIA and NIH test results indicated the high specificity of S053 and S036 MAbs. These preliminary results supported the hypothesis that in vivo immunogenicity may be predicted from the in vitro assay of glycoprotein using the specific glycoprotein MAb.

We have described the establishment and preliminary validation of this novel TRFIA for the assay of rabies virus glycoprotein in rabies vaccines, and the method demonstrated satisfactory results when applied in practical samples. The minimum detectable dose of the present TRFIA was as low as 0.098 IU/ml. Thus, those samples with lower values could easily be detected by the present TRFIA. Samples with high values could be detected without dilution based on the detection range can be up to 500 IU/ml. The measurement of parameters was acceptable compared with other TRFIA and ELISA, and better than most conventional ELISA. Correlation coefficient (r² = 0.902) suggested that TRFIA and ELISA results showed good correlation. Due to its wider detection range and shorter reaction time, the present TRFIA can greatly save the operation time and workload for quality control in each stage of vaccine production. Base on the excellent measurement of parameters of the present TRFIA, we claimed that the present TRFIA could replace ELISA with credible results and rapid detection. It could perform as well as NIH test when applied to evaluation of the potency of rabies vaccine samples. What is more, this method demonstrated high sensitivity, wider effective detection range and excellent reproducibility for the assay of rabies virus glycoprotein, and offered additional benefit for rapid detection, resulting in a substantially faster assay. At present, it is a feasible and more suitable tool for the quality control in the process of vaccines production, such as monitoring the production consistency of the rabies vaccines prior to their release to the market. We have reasons to believe that the present TRFIA should be a new and interesting methodology for the rabies vaccines field of potency testing. Based on this research, we established a good foundation for further development of the dual-label time-resolved fluoroimmunoassay for rabies glycoprotein and nucleoprotein by using the same platform as we did in our past research. Direct labeling of immune reagents with lanthanide chelates and lack of overlapping between Eu³⁺ and Sm³⁺ chelates allow to save more time and workload.

Figure 6. Graphical comparisons of the present TRFIA and NIH test results for evaluation of the potency of rabies vaccine samples.

![Graphical comparisons of the present TRFIA and NIH test results for evaluation of the potency of rabies vaccine samples.](https://www.nature.com/scientificreports/)
References

1. Dodet, B. & Asian Rabies Expert, B. An important date in rabies history. *Vaccine* **25**, 8647–8650 (2007).

2. Nimmagadda, S. V. *et al.* Recombinant diabody-based immunocapture enzyme-linked immunosorbent assay for quantification of rabies virus glycoprotein. *Clin. Vaccine Immunol.* **17**, 1261–1268 (2010).

3. Yokomizo, A. Y. *et al.* Rabies virus glycoprotein expression in Drosophila S2 cells. I. Functional recombinant protein in stable co-transfected cell line. *Biotechnology journal* **2**, 102–109 (2007).

4. Moore, M. C. *et al.* Comparison of anamnestic responses to rabies vaccination in dogs and cats with current and out-of-date vaccine status. *J Am Vet Med Assoc* **246**, 205–211 (2015).

5. Smith, T. G. *et al.* An electrochemiluminescence assay for analysis of rabies virus glycoprotein content in rabies vaccines. *Vaccine* **31**, 3333–3338 (2013).

6. Lyng, J., Bentzon, M. W., Ferguson, M. & Fitzgerald, E. A. Rabies vaccine standardization: International Collaborative Study for the Characterization of the fifth International Standard for Rabies Vaccine. *Biologicals* **20**, 301–313 (1992).

7. Barth, R., Diderrich, G. & Weinmann, E. NIH test, a problematic method for testing potency of inactivated rabies vaccine. *Vaccine* **6**, 369–377 (1988).

8. Perrin, P., Morgeaux, S. & Sureau, P. *In vitro* rabies vaccine potency appraisal by ELISA: advantages of the immunocapture method with a neutralizing anti-glycoprotein monoclonal antibody. *Biologicals* **18**, 321–330 (1990).

9. Wunner, W. H., Larson, J. K., Dietzschold, B. & Smith, C. L. The molecular biology of rabies viruses. *Rev. Infect. Dis.* **10** (Suppl 4), S771–S784 (1988).

10. Nagarajan, T. *et al.* A simple immuno-capture ELISA to estimate rabies viral glycoprotein antigen in vaccine manufacture. *Biologicals* **34**, 21–27 (2006).

11. Ferguson, M. & Heath, A. Report of a collaborative study to assess the determination of glycoprotein antigen content of rabies vaccines for human use. *Biologicals* **20**, 143–154 (1992).

12. Lafon, M., Perrin, P., Versmisse, P. & Sureau, P. Use of a monoclonal antibody for quantitation of rabies vaccine glycoprotein by enzyme immunoassay. *J. Biol. Stand.* **13**, 295–301 (1985).

13. Fitzgerald, E. A. & Needy, C. F. Use of the single radial immunodiffusion test as a replacement for the NIH mouse potency test for rabies vaccine. *Dev. Biol. Stand.* **64**, 73–79 (1986).

14. Ferguson, M. & Schild, G. C. A single-radial immunodiffusion technique for the assay of rabies glycoprotein antigen: application for potency tests of vaccines against rabies. *J Gen Virol* **59**, 197–201 (1982).

15. Thraenhart, O. & Ramakrishnan, K. Standardization of an enzyme immunoassay for the *in vitro* potency assay of inactivated tissue culture rabies vaccines: determination of the rabies virus glycoprotein with polyclonal antiserum. *J. Biol. Stand.* **17**, 291–309 (1989).

16. Fournier-Carauana, J. *et al.* Inactivated rabies vaccine control and release: use of an ELISA method. *Biologicals* **31**, 9–16 (2003).

17. Mousli, M.,Turki, I., Kharmachi, H., Saadi, M. & Dellagi, K. Recombinant single-chain Fv antibody fragment-alkaline phosphatase conjugate: a novel *in vitro* tool to estimate rabies viral glycoprotein antigen in vaccine manufacture. *J Virol Methods* **146**, 246–256 (2007).

18. Lovgren, T., Hemmla, I., Pettersson, K., Eskola, J. U. & Bertof, E. Determination of hormones by time-resolved fluoroimmunoassay. *Talanta* **31**, 909–916 (1984).

19. Dickson, E. F., Pollak, A. & Diamandis, E. P. Ultrasensitive bioanalytical assays using time-resolved fluorescence detection. *Pharmacol. Ther.* **66**, 207–235 (1995).

20. Hemmla, I. Fluorimmunoassays and immunofluorometric assays. *Clin Chem* **31**, 359–370 (1985).

21. Hemmla, I., Dakuubu, S., Mukkala, V. M., Sittari, H. & Lovgren, T. Europium as a label in time-resolved immunofluorometric assays. *Anal Biochem* **137**, 335–343 (1984).

22. Kricka, L. J. Selected strategies for improving sensitivity and reliability of immunofluorometric assays. *Clin Chem* **40**, 347–357 (1994).

23. Lin, G. F., Liu, T. C., Zou, L. P., Hou, J. Y. & Wu, Y. S. Development of a dual-label time-resolved fluoroimmunoassay for the detection of alpha-fetoprotein and hepatitis B virus surface antigen. *Luminescence* **28**, 401–406 (2013).

24. Lin, G. *et al.* A time-resolved fluoroimmunoassay for the quantitation of rabies virus nucleoprotein in the rabies vaccine. *J Virol Methods* **206**, 89–94 (2014).

25. Lin, G. F. *et al.* Simultaneous determination of the cytokeratin 19 fragment and carcinoembryonic antigen in human serum by magnetic nanoparticle-based dual-label time-resolved fluoroimmunoassay. *RSC Adv* **4**, 55229–55236 (2015).

26. Zhao, H. *et al.* Rapid quantitation of human epididymis protein 4 in human serum by amplified luminescent proximity homogeneous immunoassay (AlphaLISA). *J Immunol Methods* **347**, 64–69 (2016).

27. Pei, X. *et al.* Sandwich-type immunosensors and immunoassays exploiting nanostructure labels: A review. *Anal Chim Acta* **758**, 1–18 (2013).

28. Howard, G. C. & Kaser, M. R. Making and Using Antibodies. *Taylor & Francis Group, LLC.* (2007).

29. Seligmann, E. B. Jr. Laboratory techniques in rabies: the NIH test for potency. *Biologicals* **18**, 321–330 (1990).

30. Wunner, W. H., Larson, J. K., Dietzschold, B. & Smith, C. L. The molecular biology of rabies viruses. *Rev. Infect. Dis.* **10** (Suppl 4), S771–S784 (1988).

31. Smith, T. G. *et al.* An electrochemiluminescence assay for analysis of rabies virus glycoprotein content in rabies vaccines. *Vaccine* **31**, 3333–3338 (2013).

32. Ly, X. J. *et al.* Preparation and initial application of a monoclonal antibody specific for a newly discovered conserved linear epitope of rabies virus nucleoprotein. *Biomed. Environ. Sci.* **25**, 98–103 (2012).

33. He, Y., Gao, D. & Zhang, M. Expression of the nucleoprotein gene of rabies virus for use as a diagnostic reagent. *J. Virol. Methods* **138**, 147–151 (2006).

34. Wunner, W. H., Dietzschold, B., Curtis, P. J. & Wiktor, T. J. Rabies subunit vaccines. *J Gen Virol* **64**(Pt 8), 1649–1656 (1983).

35. Hou, J. Y. *et al.* Development of an immunomagnetic bead-based time-resolved fluorescence immunoassay for rapid determination of levels of carcinoembryonic antigen in human serum. *Anal Chim Acta* **734**, 93–98 (2012).

36. Lin, G. F. *et al.* A magnetic nanoparticle-based time-resolved fluoroimmunoassay for determination of the cytokeratin 19 fragment in human serum. *J Fluoresc* **25**, 361–367 (2015).

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Grant No. 21575058), China Postdoctoral Science Foundation (Grant No. 2016M606662) and Scientific Research Initiation Plan of Southern Medical University (Grant No. QD2016N006).

Author Contributions

Yingsong Wu designed the study, Guanfeng Lin, Shaolang Chen and Hui Zhao performed the *in vitro* experiment, Tiancai Liu, Junyu Liang and Qiaoting Deng performed the *in vivo* experiments on mice, Guanfeng Lin and Hui Zhao wrote the manuscript, Rongliang Liang, Xinxin Guo, Zhenhua Chen and Baihong Chen analyzed data, and all authors read and approved the final version of manuscript.
Additional Information

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017